{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:57:49Z","timestamp":1781611069992,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hefei Municipal Key Technology Research and Development Program","award":["GJ2022SM01"],"award-info":[{"award-number":["GJ2022SM01"]}]},{"name":"Key Scientific Research Foundation of the Education Department of Anhui Province","award":["2024AH050828"],"award-info":[{"award-number":["2024AH050828"]}]},{"name":"Research Fund of Anhui Institute of Translational Medicine","award":["No. 2023zhyx-B03"],"award-info":[{"award-number":["No. 2023zhyx-B03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder carcinoma (BC) is a malignant tumor that originates from the epithelial cells of the urinary system. Currently, the main diagnostic methods suffer from disadvantages including being invasive, having high costs, and low sensitivity and specificity. Therefore, there is an urgent need to develop a non-invasive, high-performance method for diagnosing BC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We developed a urine DNA detection panel utilizing two methylation biomarkers for the diagnosis of BC. A total of 467 urine samples were collected from the First Affiliated Hospital of Anhui Medical University for DNA methylation analysis. The methylation levels of Vimentin and POU class 4 homeobox 2 gene (POU4F2) were analyzed in a training set of 306 urine samples (92 cases and 214 controls), and in an independent validation set of 161 urine samples (59 cases and 102 controls) using Real-Time PCR (RT-PCR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The Vimentin\/POU4F2 combined methylation panel achieved an AUC of 0.935 (95% CI: 0.889\u20130.981), with sensitivity, specificity, and accuracy of 86.44% (95% CI: 0.772\u20130.957), 96.08% (95% CI: 0.923\u20130.998), and 92.55% (95% CI: 0.886\u20130.965) for diagnosing BC. Notably, for patients with stage I and low-grade BC, the sensitivity was 90.00% for both. Additionally, it demonstrated specificities of 96.30% and 95.83% for patients with other urinary diseases and malignancies in other systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study provides evidence that the two-gene methylation panel based on urine DNA detection demonstrates strong performance in diagnosing BC with high sensitivity and accuracy, offering a promising strategy for early screening and adjunctive diagnosis of BC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-14795-5","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:45:25Z","timestamp":1759229125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The diagnostic performance of a noninvasive urine-based methylation biomarkers Vimentin\/POU4F2 to detect bladder carcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Jialong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanjiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"14795_CR1","doi-asserted-by":"publisher","first-page":"103112","DOI":"10.1016\/j.critrevonc.2020.103112","volume":"156","author":"D Connors","year":"2020","unstructured":"Connors D, Allen J, Alvarez JD, et al. International liquid biopsy standardization alliance white paper. Crit Rev Oncol Hematol. 2020;156:103112.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6485","key":"14795_CR2","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1126\/science.abb0736","volume":"367","author":"N Ma","year":"2020","unstructured":"Ma N, Jeffrey SS. Deciphering cancer clues from blood. Science. 2020;367(6485):1424\u20135.","journal-title":"Science"},{"issue":"1","key":"14795_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81(1):75\u201394.","journal-title":"Eur Urol"},{"issue":"12","key":"14795_CR4","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.ccell.2024.11.001","volume":"42","author":"X Wu","year":"2024","unstructured":"Wu X, Sheng X. Molecular subtyping in urothelial carcinoma treatment. Cancer Cell. 2024;42(12):1993\u20136.","journal-title":"Cancer Cell"},{"issue":"20","key":"14795_CR5","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.3390\/cancers15205020","volume":"15","author":"Z Wang","year":"2023","unstructured":"Wang Z, Shi H, Xu Y, et al. Intravesical Therapy for Upper Urinary Tract Urothelial Carcinoma: A Comprehensive Review. Cancers (Basel). 2023;15(20):5020.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"14795_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","volume":"66","author":"RS Svatek","year":"2014","unstructured":"Svatek RS, Hollenbeck BK, Holm\u00e4ng S, et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol. 2014;66(2):253\u201362.","journal-title":"Eur Urol"},{"issue":"1","key":"14795_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3892\/ol.2016.4556","volume":"12","author":"H He","year":"2016","unstructured":"He H, Han C, Hao L, Zang G. ImmunoCyt test compared to cytology in the diagnosis of bladder cancer: A meta-analysis. Oncol Lett. 2016;12(1):83\u20138.","journal-title":"Oncol Lett"},{"issue":"3","key":"14795_CR8","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3390\/tomography9030075","volume":"9","author":"M Cellina","year":"2023","unstructured":"Cellina M, C\u00e8 M, Rossini N, et al. Computed Tomography Urography: State of the Art and Beyond. Tomography. 2023;9(3):909\u201330.","journal-title":"Tomography"},{"issue":"2","key":"14795_CR9","doi-asserted-by":"publisher","first-page":"66.e25","DOI":"10.1016\/j.urolonc.2014.06.008","volume":"33","author":"FA Yafi","year":"2015","unstructured":"Yafi FA, Brimo F, Steinberg J, et al. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol. 2015;33(2):66.e25-31.","journal-title":"Urol Oncol"},{"issue":"5","key":"14795_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/j.1464-410X.2010.09899.x","volume":"108","author":"J Messer","year":"2011","unstructured":"Messer J, Shariat SF, Brien JC, et al. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int. 2011;108(5):701\u20135.","journal-title":"BJU Int"},{"issue":"1","key":"14795_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"issue":"5","key":"14795_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1586\/14737159.7.5.519","volume":"7","author":"H Shi","year":"2007","unstructured":"Shi H, Wang MX, Caldwell CW. CpG islands: their potential as biomarkers for cancer. Expert Rev Mol Diagn. 2007;7(5):519\u201331.","journal-title":"Expert Rev Mol Diagn"},{"issue":"2","key":"14795_CR13","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/bju.15194","volume":"127","author":"P Gontero","year":"2021","unstructured":"Gontero P, Montanari E, Roupret M, et al. Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study. BJU Int. 2021;127(2):198\u2013204.","journal-title":"BJU Int"},{"key":"14795_CR14","first-page":"336","volume":"9","author":"L Ma","year":"2024","unstructured":"Ma L, Guo H, Zhao Y, et al. Liquid biopsy in cancer: current status, challenges and future prospects. Nature. 2024;9:336.","journal-title":"Nature"},{"issue":"1","key":"14795_CR15","doi-asserted-by":"publisher","first-page":"21685","DOI":"10.1038\/s41598-023-48501-x","volume":"13","author":"C Alix-Panabi\u00e8res","year":"2023","unstructured":"Alix-Panabi\u00e8res C, Marchetti D, Lang JE. Liquid biopsy: from concept to clinical application. Sci Rep. 2023;13(1):21685.","journal-title":"Sci Rep"},{"issue":"5","key":"14795_CR16","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1111\/cas.14000","volume":"110","author":"Y Hayashi","year":"2019","unstructured":"Hayashi Y, Fujita K, Matsuzaki K, et al. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma. Cancer Sci. 2019;110(5):1771\u20139.","journal-title":"Cancer Sci"},{"issue":"1","key":"14795_CR17","doi-asserted-by":"publisher","first-page":"7941","DOI":"10.1038\/s41598-024-58586-7","volume":"14","author":"C Zhang","year":"2024","unstructured":"Zhang C, Xu X, Wang T, Lu Y, Lu Z, Wang T, Pan Z. Clinical performance and utility of a noninvasive urine-based methylation biomarker: TWIST1\/Vimentin to detect urothelial carcinoma of the bladder. Sci Rep. 2024;14(1):7941.","journal-title":"Sci Rep"},{"issue":"2","key":"14795_CR18","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.euf.2018.09.016","volume":"6","author":"Y Wu","year":"2020","unstructured":"Wu Y, Jiang G, Zhang N, Liu S, Lin X, Perschon C, Zheng SL, Ding Q, Wang X, Na R, et al. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria. Eur Urol Focus. 2020;6(2):284\u201391.","journal-title":"Eur Urol Focus"},{"issue":"3","key":"14795_CR19","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.urology.2010.07.498","volume":"77","author":"C Xu","year":"2011","unstructured":"Xu C, Zeng Q, Hou J, Gao L, Zhang Z, Xu W, Yang B, Sun Y. Utility of a modality combining FISH and cytology in upper tract urothelial carcinoma detection in voided urine samples of Chinese patients. Urology. 2011;77(3):636\u201341.","journal-title":"Urology"},{"issue":"5","key":"14795_CR20","doi-asserted-by":"publisher","first-page":"e0149185","DOI":"10.1371\/journal.pone.0149185","volume":"11","author":"J Yang","year":"2016","unstructured":"Yang J, Niu H, Huang Y, Yang K. A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis. PLoS ONE. 2016;11(5):e0149185.","journal-title":"PLoS ONE"},{"issue":"1","key":"14795_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.gep.2014.03.001","volume":"15","author":"M Deng","year":"2014","unstructured":"Deng M, Yang H, Xie X, Liang G, Gan L. Comparative expression analysis of POU4F1, POU4F2 and ISL1 in developing mouse cochleovestibular ganglion neurons. Gene Expr Patterns. 2014;15(1):31\u20137.","journal-title":"Gene Expr Patterns"},{"key":"14795_CR22","doi-asserted-by":"publisher","first-page":"7287","DOI":"10.1038\/ncomms8287","volume":"6","author":"D P\u00e9rez-Sala","year":"2015","unstructured":"P\u00e9rez-Sala D, Oeste CL, Mart\u00ednez AE, et al. Vimentin filament organization and stress sensing depend on its single cysteine residue and zinc binding. Nature Commun. 2015;6:7287.","journal-title":"Nature Commun"},{"issue":"11","key":"14795_CR23","doi-asserted-by":"publisher","first-page":"166524","DOI":"10.1016\/j.bbadis.2022.166524","volume":"1868","author":"NK Poddar","year":"2022","unstructured":"Poddar NK, Agarwal D, Agrawal Y, et al. Deciphering the enigmatic crosstalk between prostate cancer and Alzheimer\u2019s disease: A current update on molecular mechanisms and combination therapy. Biochim Biophys Acta Mol Basis Dis. 2022;1868(11):166524.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"19","key":"14795_CR24","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.3390\/cancers13194985","volume":"13","author":"S Usman","year":"2021","unstructured":"Usman S, Waseem NH, Nguyen TKN, et al. Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis. Cancers (Basel). 2021;13(19):4985.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"14795_CR25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejca.2013.08.025","volume":"50","author":"S Monteiro-Reis","year":"2014","unstructured":"Monteiro-Reis S, Le\u00e7a L, Almeida M, et al. Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation. Eur J Cancer. 2014;50(1):226\u201333.","journal-title":"Eur J Cancer"},{"issue":"23","key":"14795_CR26","doi-asserted-by":"publisher","first-page":"5842","DOI":"10.1158\/1078-0432.CCR-10-1312","volume":"16","author":"VL Costa","year":"2010","unstructured":"Costa VL, Henrique R, Danielsen SA, et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res. 2010;16(23):5842\u201351.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"14795_CR27","doi-asserted-by":"publisher","first-page":"935.e1","DOI":"10.1016\/j.urolonc.2020.06.012","volume":"38","author":"AA Elsawy","year":"2020","unstructured":"Elsawy AA, Harraz AM, Ghobrial FK, Abdullatef M, Ali-El-Dein B. Diagnostic performance and predictive capacity of early urine cytology after transurethral resection of nonmuscle invasive bladder cancer: A prospective study. Urol Oncol. 2020;38(12):935.e1-935.e8.","journal-title":"Urol Oncol"},{"issue":"10","key":"14795_CR28","doi-asserted-by":"publisher","first-page":"6554","DOI":"10.21037\/tcr-20-1990","volume":"9","author":"HH Lee","year":"2020","unstructured":"Lee HH, Kim SH. Review of non-invasive urinary biomarkers in bladder cancer. Transl Cancer Res. 2020;9(10):6554\u201364.","journal-title":"Transl Cancer Res"},{"key":"14795_CR29","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1186\/1471-2407-12-551","volume":"12","author":"S Snellenberg","year":"2012","unstructured":"Snellenberg S, De Strooper LM, Hesselink AT, et al. Development of a multiplex methylation-specific PCR as candidate triage test for women with an HPV-positive cervical scrape. BMC Cancer. 2012;12:551.","journal-title":"BMC Cancer"},{"issue":"3","key":"14795_CR30","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"14795_CR31","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.21873\/anticanres.14334","volume":"40","author":"HH Koh","year":"2020","unstructured":"Koh HH, Lee MJ, Park NJ, et al. Impact of Implementing the Paris System for Reporting Urinary Cytology: A Single-institutional Experience With Emphasis on Diagnostic Yield of High-grade Urothelial Carcinoma and Low-grade Urothelial Neoplasm. Anticancer Res. 2020;40(6):3477\u201384.","journal-title":"Anticancer Res"},{"issue":"12","key":"14795_CR32","doi-asserted-by":"publisher","first-page":"922","DOI":"10.7326\/M15-0997","volume":"163","author":"R Chou","year":"2015","unstructured":"Chou R, Gore JL, Buckley D, Fu R, Gustafson K, Griffin JC, et al. Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;163(12):922\u201331.","journal-title":"Ann Intern Med"},{"issue":"9","key":"14795_CR33","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nrg.2016.83","volume":"17","author":"H Zhu","year":"2016","unstructured":"Zhu H, Wang G, Qian J. Transcription factors as readers and effectors of DNA methylation. Nat Rev Genet. 2016;17(9):551\u201365.","journal-title":"Nat Rev Genet"},{"issue":"5","key":"14795_CR34","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/S0022-5347(05)67104-2","volume":"164","author":"KC Halling","year":"2000","unstructured":"Halling KC, King W, Sokolova IA, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol. 2000;164(5):1768\u201375.","journal-title":"J Urol"},{"issue":"10","key":"14795_CR35","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41576-022-00477-6","volume":"23","author":"K Seale","year":"2022","unstructured":"Seale K, Horvath S, Teschendorff A, et al. Making sense of the ageing methylome. Nat Rev Genet. 2022;23(10):585\u2013605.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"14795_CR36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s13059-019-1824-y","volume":"20","author":"CG Bell","year":"2019","unstructured":"Bell CG, Lowe R, Adams PD, et al. DNA methylation aging clocks: challenges and recommendations. Genome Biol. 2019;20(1):249.","journal-title":"Genome Biol"},{"issue":"9","key":"14795_CR37","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/s43587-023-00462-6","volume":"3","author":"AT Lu","year":"2023","unstructured":"Lu AT, Fei Z, Haghani A, et al. Universal DNA methylation age across mammalian tissues. Nat Aging. 2023;3(9):1144\u201366.","journal-title":"Nat Aging"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14795-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14795-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14795-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:50:48Z","timestamp":1781610648000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-14795-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14795"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14795-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The participants were enrolled at the First Affiliated Hospital of Anhui Medical University. All subjects signed the informed consent before urine collection, and they were informed of the usage of urine and the test results. Ethical approval was granted by the Medical Ethics Committees of the First Affiliated Hospital of Anhui Medical University, and all procedures adhered to the ethical standards outlined in the Declaration of Helsinki (or other relevant guidelines). Additional documentation (e.g., consent forms) can be provided upon request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1460"}}